Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
5 participants
INTERVENTIONAL
2017-03-08
2021-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Ulcerative Colitis Diet
Participants will receive a structured 12-week diet with a step down phase.
Ulcerative Colitis Diet (UCD)
The primary study intervention is a novel dietary intervention, the UC Diet. The UC Diet is a structured 12-week diet with a step down phase designed to remove products that allow harmful bacteria to thrive and add products that can change the bacteria in the gut to induce remission
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Ulcerative Colitis Diet (UCD)
The primary study intervention is a novel dietary intervention, the UC Diet. The UC Diet is a structured 12-week diet with a step down phase designed to remove products that allow harmful bacteria to thrive and add products that can change the bacteria in the gut to induce remission
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Established diagnosis of UC
* Age: 8-19 (inclusive)
* Mild to moderate active disease, 10\<PUCAI\<45
* Stable medication (IMM/5ASA) use or no medication use for the past 6 weeks.
* Participant has agreed to follow the UCD for 12 weeks
Exclusion Criteria
* Antibiotic or corticosteroid use in the past 2 weeks
* Use of biologics in present or in the past
* PUCAI\>45
* Acute severe UC in the previous 12 months
* Current extra intestinal manifestation of UC
* Primary Sclerosing Cholangitis (PSC) or liver disease
* Pregnancy
* Known food allergy to mandatory foods in the UCD
8 Years
19 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Wolfson Medical Center
OTHER_GOV
IWK Health Centre
OTHER
National Institutes of Health (NIH)
NIH
Children's Hospital of Philadelphia
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Lindsey Albenberg, DO
Role: PRINCIPAL_INVESTIGATOR
Children's Hospital of Philadelphia
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
The Children's Hospital of Philadelphia
Philadelphia, Pennsylvania, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
16-013075
Identifier Type: -
Identifier Source: org_study_id